Treatment of alcohol dependence with low-dose topiramate: An open-label controlled study

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Paparrigopoulos, Thomas ^a   Tzavellas, Elias ^a   Karaiskos, Dimitris ^a   Kourlaba, Georgia ^b   Liappas, Ioannis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ANXIETY; ARTICLE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DETOXIFICATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; PARESTHESIA; PSYCHOMOTOR PERFORMANCE; RELAPSE; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PSYCHOTHERAPY;

ADULT; ALCOHOLISM; ANTICONVULSANTS; ANXIETY; COMBINED MODALITY THERAPY; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 79952510704     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-41     Document Type: Article

References (48)

1. Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm RJ. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res 2004, 28(2):295-301. 10.1097/01.ALC.0000113409.47937.6C, 15112937.
2. Lobo IA, Harris RA. GABA(A) receptors and alcohol. Pharmacol Biochem Behav 2008, 90(1):90-94. 10.1016/j.pbb.2008.03.006, 2574824, 18423561.
3. Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, Llorca J. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr 2010, 38(1):8-12.
4. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010, 16(19):2103-2112. 10.2174/138161210791516404, 20482511.
5. Deng C, Li KY, Zhou C, Ye JH. Ethanol enhances glutamate transmission by retrograde dopamine signaling in a postsynaptic neuron/synaptic bouton preparation from the ventral tegmental area. Neuropsychopharmacology 2009, 34(5):1233-1244. 10.1038/npp.2008.143, 2761034, 18784647.
6. Xiao C, Shao XM, Olive MF, Griffin WC, Li KY, Krnjevic K, Zhou C, Ye JH. Ethanol facilitates glutamatergic transmission to dopamine neurons in the ventral tegmental area. Neuropsychopharmacology 2009, 34(2):307-318. 10.1038/npp.2008.99, 2676579, 18596684.
7. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006, 111(3):855-876. 10.1016/j.pharmthera.2006.02.001, 16545872.
8. Johnson BA. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res 2004, 28(8):1137-1144. 10.1097/01.ALC.0000134533.96915.08, 15318111.
9. Kleber HD, Weiss RD, Anton RF, George TP, Greenfield SF, Kosten TR, O'Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry 2007, 164(4 Suppl):5-123.
10. Driessen M, Meier S, Hill A, Wetterling T, Lange W, Junghanns K. The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol 2001, 36(3):249-255.
11. Willinger U, Lenzinger E, Hornik K, Fischer G, Schonbeck G, Aschauer HN, Meszaros K. Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol Alcohol 2002, 37(6):609-612.
12. Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(1):55-60. 10.1016/j.pnpbp.2004.10.005, 15610945.
13. Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008, 154(2):299-315. 10.1038/bjp.2008.30, 2442440, 18311194.
14. Chiu YH, Lee TH, Shen WW. Use of low-dose topiramate in substance use disorder and bodyweight control. Psychiatry Clin Neurosci 2007, 61(6):630-633. 10.1111/j.1440-1819.2007.01718.x, 18081623.
15. Martinotti G, Di Nicolaa M, De Vitaa O, Tedeschia D, Guerrieroa L, Guglielmoa R, De Filippisa R, Janiri L. Low-dosage topiramate in alcohol dependence: a randomized, double-blind, placebo-controlled trial. European Psychiatry, 18th European Congress of Psychiatry, Poster: 2010 2010, 1665.
16. Diagnostic and statistical manual of mental disorders DSM-IV-TR (Revised 4th ed). 2000, Washington, DC: American Psychiatric Association.
17. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990, 47(6):589-593.
18. Magura S, Kang SY. Validity of self-reported drug use in high risk populations: a meta-analytical review. Subst Use Misuse 1996, 31(9):1131-1153. 10.3109/10826089609063969, 8853234.
19. Salaspuro M. Carbohydrate-deficient transferrin as compared to other markers of alcoholism: a systematic review. Alcohol 1999, 19(3):261-271. 10.1016/S0741-8329(99)00044-0, 10580517.
20. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, et al. The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988, 45(12):1069-1077.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62. 10.1136/jnnp.23.1.56, 495331, 14399272.
22. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959, 32(1):50-55.
23. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995, 19(1):92-99. 10.1111/j.1530-0277.1995.tb01475.x, 7771669.
24. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33(6):766-771.
25. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989, 84(11):1353-1357. 10.1111/j.1360-0443.1989.tb00737.x, 2597811.
26. Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl 2005, (15):157-167. discussion 140.
27. Olive MF. Pharmacotherapies for alcoholism: the old and the new. CNS Neurol Disord Drug Targets 2010, 9(1):2-4.
28. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361(9370):1677-1685. 10.1016/S0140-6736(03)13370-3, 12767733.
29. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. Jama 2007, 298(14):1641-1651. 10.1001/jama.298.14.1641, 17925516.
30. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008, 103(12):2035-2044. 10.1111/j.1360-0443.2008.02355.x, 18855810.
31. De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 2008, 34(4):460-463. 10.1016/j.jsat.2007.05.012, 17629442.
32. Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the Treatment of Alcohol Dependence: Comparison with Naltrexone. Eur Addict Res 2010, 17(1):29-36. 10.1159/000320471, 20975274.
33. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008, 75(1):218-265. 10.1016/j.bcp.2007.06.039, 2239014, 17706608.
34. Roberto M, Madamba SG, Moore SD, Tallent MK, Siggins GR. Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons. Proc Natl Acad Sci USA 2003, 100(4):2053-2058. 10.1073/pnas.0437926100, 149957, 12566570.
35. Enoch MA. The role of GABA(A) receptors in the development of alcoholism. Pharmacol Biochem Behav 2008, 90(1):95-104. 10.1016/j.pbb.2008.03.007, 2577853, 18440057.
36. Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother 2008, 42(10):1475-1480. 10.1345/aph.1L157, 18698008.
37. Luykx JJ, Carpay JA. Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf 2010, 9(4):623-631. 10.1517/14740331003739196, 20367527.
38. Meador KJ. Cognitive effects of levetiracetam versus topiramate. Epilepsy Curr 2008, 8(3):64-65. 10.1111/j.1535-7511.2008.00239.x, 2384151, 18488056.
39. Charney DA, Zikos E, Gill KJ. Early recovery from alcohol dependence: factors that promote or impede abstinence. J Subst Abuse Treat 2010, 38(1):42-50. 10.1016/j.jsat.2009.06.002, 19632079.
40. Dawe S, Loxton NJ. The role of impulsivity in the development of substance use and eating disorders. Neurosci Biobehav Rev 2004, 28(3):343-351. 10.1016/j.neubiorev.2004.03.007, 15225976.
41. Koob GF. Animal models of craving for ethanol. Addiction 2000, 95(Suppl 2):S73-81.
42. Prado-Lima PA. [Pharmacological treatment of impulsivity and aggressive behavior]. Rev Bras Psiquiatr 2009, 31(Suppl 2):S58-65.
43. Leung KS, Cottler LB. Treatment of pathological gambling. Curr Opin Psychiatry 2009, 22(1):69-74. 10.1097/YCO.0b013e32831575d9, 19122538.
44. McElroy SL, Guerdjikova AI, Martens B, Keck PE, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009, 23(2):139-156. 10.2165/00023210-200923020-00004, 19173373.
45. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2010,
46. Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Impact of alcohol detoxification on anxiety and depressive symptoms. Drug Alcohol Depend 2002, 68(2):215-220. 10.1016/S0376-8716(02)00195-3, 12234651.
47. Paparrigopoulos T, Tzavellas E, Karaiskos D, Malitas P, Liappas I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J Psychopharmacol 2010, 24(9):1375-1380. 10.1177/0269881109103799, 19346278.
48. Bottlender M, Soyka M. Impact of craving on alcohol relapse during, and 12 months following, outpatient treatment. Alcohol Alcohol 2004, 39(4):357-361.